Despite a 15% gain in Outlook Therapeutics, Inc.’s (NASDAQ:OTLK) stock price this week, shareholders shouldn’t let up. Even though stock prices were relatively low, insiders elected to sell US$1.1m worth of stock in the last year, which could indicate some expected downturn.
Although we don’t think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
See our latest analysis for Outlook Therapeutics
The Last 12 Months Of Insider Transactions At Outlook Therapeutics
Over the last year, we can see that the biggest insider sale was by the Chief Operations Officer, Terry Dagnon, for US$590k worth of shares, at about US$1.14 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$0.46). So it may not shed much light on insider confidence at current levels.
In the last year Outlook Therapeutics insiders didn’t buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
I will like Outlook Therapeutics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Does Outlook Therapeutics Boast High Insider Ownership?
Many investors like to check how much of a company is owned by insiders. I reckon it’s a good sign if insiders own a significant number of shares in the company. From our data, it seems that Outlook Therapeutics insiders own 7.4% of the company, worth about US$8.4m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We do generally prefer see higher levels of insider ownership.
So What Does This Data Suggest About Outlook Therapeutics Insiders?
The fact that there have been no Outlook Therapeutics insider transactions recently certainly doesn’t bother us. Our analysis of Outlook Therapeutics insider transactions leaves us unenthusiastic. We also note that, as far as we can see, insider ownership is fairly low, compared to other companies. In addition to knowing about insider transactions going on, it’s beneficial to identify the risks facing Outlook Therapeutics. Our analysis shows 5 warning signs for Outlook Therapeutics (3 are potentially serious!) and we strongly recommend you look at these before investing.
Of course Outlook Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Valuation is complex, but we’re helping make it simple.
Find out whether Outlook Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
